Description
Scope of the Report The report titled “ Global PAH Market : Trends and Opportunities ( 2015-2019 )”, analyzes the potential opportunities and significant trends in the global Pulmonary Arterial Hypertension ( PAH ) market . The market size and forecast in value terms for global PAH market has been provided for the period 2010 to 2019 , considering 2014 as the base year . The report also provides the compounded annual growth rate (% CAGR ) for the forecast period 2015 to 2019 . Over the next five years , Global PAH market revenue is forecasted to remain stable due to patent expiries and launch of new drugs .
Request a sample of this report @ http :// www . orbisresearch . com / contacts / request-sample / 185293 .
The report provides detailed analysis of the global PAH market sizing and growth by type for the period 2010-2014 . The market is further segment by drug mechanism and different dosage forms . The analysis of PAH individual drugs sales are also provided in the report .
The report profiles key market players such as Actelion Ltd ., United Therapeutics Ltd . and SteadyMed Ltd . on the basis of attributes such as company overview , recent developments , strategies adopted by the market leaders to ensure growth , sustainability , financial overview and recent developments .
Purchase a copy of Global Pulmonary Arterial Hypertension ( PAH ) Market visit @ http :// www . orbisresearch . com / contact / purchase / 185293 For more information contact sales @ orbisresearch . com .
Company Coverage Actelion Limited United Therapeutics Limited SteadyMed Limited
PAH Drug Mechanism Endothelin Receptor Antagonists ( ERA ) PDE 5 Inhibitors Prostacyclins sGC Stimulator
Executive Summary Pulmonary Arterial Hypertension ( PAH ) is a disease in which high blood pressure occurs in the right ventricle of the heart and the pulmonary arteries that supply blood to the lungs . The increase in pressure is caused by constriction and narrowing of the small pulmonary arteries . In 2005 , standard of care was characterized by intravenous treatment aimed at reducing symptoms , not addressing root cause . Now , new treatments are available that go beyond symptom management to treat the underlying cause of PAH . With advancement in the standard of care , patients are able to maintain active lifestyles with a reduced risk of serious heart events associated with PAH .
www . orbisresearch . com ; + 1 ( 214 ) 884-6817 ; + 9120-64101019